Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins

[1]  C. Guguen-Guillouzo,et al.  Automated detection of hepatotoxic compounds in human hepatocytes using HepaRG cells and image-based analysis of mitochondrial dysfunction with JC-1 dye. , 2011, Toxicology and applied pharmacology.

[2]  R. Franklin,et al.  Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2. , 2011, Journal of pharmacological and toxicological methods.

[3]  Etienne Hanon,et al.  The Use of Real-Time Cell Analyzer Technology in Drug Discovery: Defining Optimal Cell Culture Conditions and Assay Reproducibility with Different Adherent Cellular Models , 2011, Journal of biomolecular screening.

[4]  Jörg C Gerlach,et al.  HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. , 2011, Journal of pharmacological and toxicological methods.

[5]  Yuichiro Kanno,et al.  A consecutive three alanine residue insertion mutant of human CAR: a novel CAR ligand screening system in HepG2 cells. , 2010, The Journal of toxicological sciences.

[6]  Christina Magkoufopoulou,et al.  Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  A. Guillouzo,et al.  Running title page Running title : Functional stability of CYP P 450 enzymes in HepaRG cells , 2009 .

[8]  J. G. Kenna,et al.  Cell based approaches for evaluation of drug-induced liver injury. , 2010, Toxicology.

[9]  B. Wen,et al.  Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s. , 2009, Chemico-biological interactions.

[10]  E. Hiyama,et al.  Evaluation of genes identified by microarray analysis in favorable neuroblastoma , 2009, Pediatric Surgery International.

[11]  S. Feinstein,et al.  Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. , 2009, Chemistry & biology.

[12]  James S MacDonald,et al.  Toxicity testing in the 21st century: a view from the pharmaceutical industry. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  A. Guillouzo,et al.  Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[14]  M. Greenberg,et al.  Toxicity Testing in the 21st Century , 2009, Risk analysis : an official publication of the Society for Risk Analysis.

[15]  F. Atienzar,et al.  Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[16]  A. Guillouzo,et al.  Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. , 2009, Toxicology and applied pharmacology.

[17]  B. Digregorio,et al.  Biobased performance bioplastic: Mirel. , 2009, Chemistry & biology.

[18]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  Guo-Dong Zhou,et al.  Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  Tommy B Andersson,et al.  Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies , 2008, Drug Metabolism and Disposition.

[21]  P. Olinga,et al.  Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  J V Castell,et al.  Cell lines: a tool for in vitro drug metabolism studies. , 2008, Current drug metabolism.

[23]  W. Schoonen,et al.  Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[24]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[25]  W. Schoonen,et al.  Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[26]  Stephen C. Harris,et al.  Rat toxicogenomic study reveals analytical consistency across microarray platforms , 2006, Nature Biotechnology.

[27]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[28]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[29]  A. Kong,et al.  Induction of phase I, II and III drug metabolism/transport by xenobiotics , 2005, Archives of pharmacal research.

[30]  B. Andrews,et al.  New Technologies and Screening Strategies for Hepatotoxicity: Use of In Vitro Models , 2005, Toxicologic pathology.

[31]  Dolores Diaz,et al.  Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. , 2004, Chemico-biological interactions.

[32]  M. T. Donato,et al.  Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[33]  J. Goldstein,et al.  The constitutive active/androstane receptor regulates phenytoin induction of Cyp2c29. , 2004, Molecular pharmacology.

[34]  H. Kanazawa,et al.  Determination of midazolam and its metabolite as a probe for cytochrome P450 3A4 phenotype by liquid chromatography-mass spectrometry. , 2004, Journal of chromatography. A.

[35]  Geraldine A Hamilton,et al.  Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[36]  N. J. Hewitt,et al.  Phase I and II enzyme characterization of two sources of HepG2 cell lines , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  Mark D. Johnson,et al.  Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. , 2004, Biochemical pharmacology.

[38]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[39]  Liang-Shang Gan,et al.  Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[40]  A. Sinskey,et al.  Disparity between changes in mRNA abundance and enzyme activity in Corynebacterium glutamicum:implications for DNA microarray analysis , 2003, Applied Microbiology and Biotechnology.

[41]  D. Lagadic-Gossmann,et al.  Liver Protection from Apoptosis Requires Both Blockage of Initiator Caspase Activities and Inhibition of ASK1/JNK Pathway via Glutathione S-Transferase Regulation* , 2002, The Journal of Biological Chemistry.

[42]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Westmoreland,et al.  Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.

[44]  C. Lindley,et al.  Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[45]  Kathy Carroll,et al.  Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes , 2000, Journal of biochemical and molecular toxicology.

[46]  A. Parkinson,et al.  Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. , 1996, Archives of biochemistry and biophysics.

[47]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[48]  O. Sugita,et al.  Drug metabolism by the human hepatoma cell, Hep G2. , 1987, Biochemical and biophysical research communications.

[49]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[50]  V. Cohn.  Drug metabolism. , 2020, Advances in biology of skin.